Journal of the American Academy of Dermatology, Journal Year: 2024, Volume and Issue: 91(6), P. S52 - S63
Published: Dec. 1, 2024
Language: Английский
The Lancet, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 1, 2025
Language: Английский
Citations
7
Expert Review of Clinical Immunology, Journal Year: 2023, Volume and Issue: 20(5), P. 525 - 545
Published: Dec. 22, 2023
Introduction Hidradenitis suppurativa (HS) is an autoinflammatory skin disease with a high unmet need for effective medical management. Clinically, it characterized by inflammatory nodules that may progress into abscesses, draining tunnels and extensive scarring, mainly affecting apocrine gland-bearing areas.
Language: Английский
Citations
27
Journal of the European Academy of Dermatology and Venereology, Journal Year: 2024, Volume and Issue: unknown
Published: Dec. 19, 2024
Abstract Introduction This second part of the S2k guidelines is an update 2015 S1 European guidelines. Objective These aim to provide accepted decision aid for selection, implementation and assessment appropriate sufficient therapy patients with hidradenitis suppurativa/acne inversa (HS). Methods The chapters have been selected after a Delphi procedure among experts/authors. Certain passages adopted without changes from previous version. Potential treatment complications are not included, being beyond scope these Results Since publication, validation new therapeutic approaches has almost completely overhauled knowledge in field HS treatment. Inflammatory nodules/abscesses/draining tunnels primary lesions, which enable classification disease severity by validated tools. In relation degree detectable inflammation, classified into inflammatory predominantly non‐inflammatory forms. While intensity form can be subdivided IHS4 mild, moderate severe treated medication accordingly, on surgical based Hurley stage affected localization. effectiveness oral tetracyclines as alternative combination clindamycin/rifampicin should noted. duration systemic antibiotic shortened 5‐day intravenous clindamycin Adalimumab, secukinumab bimekizumab subcutaneous administration approved EMA moderate‐to‐severe HS. Various procedures available disease. medical reduce inflammation remove irreversible tissue damage currently considered holistic approach. Conclusions Suitable options while considering algorithm according standardized criteria aimed at ensuring proper therapy.
Language: Английский
Citations
15
British Journal of Dermatology, Journal Year: 2025, Volume and Issue: 192(Supplement_1), P. i15 - i21
Published: Feb. 1, 2025
Abstract The therapeutic pipeline for moderate-to-severe hidradenitis suppurativa (HS) is robust. Successes and lessons learned have led to improvements in trial designs aimed at avoiding prior pitfalls, as well high placebo response HS, which remains a fundamental threat drug development. Herein, we review the evolutions HS trials over last 20 years with respect overall design, sample size, diversity enrolment, inclusion criteria, concomitant medications, rescue therapy, endpoints statistical design analysis plans. Areas of focus that merit future consideration are also highlighted.
Language: Английский
Citations
1
Annals of the Rheumatic Diseases, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 1, 2025
This systematic literature review (SLR) on efficacy outcomes was performed to inform the 2024 update of expert consensus statement treatment immune-mediated inflammatory diseases (IMIDs) with Janus kinase inhibitors (JAKi). An 2019 SLR in MEDLINE, Embase, and Cochrane Library. For efficacy, randomised, placebo (PLC)- or active-controlled trials all JAKi investigated IMIDs, as well cohort claims data for conditions where such studies were not available, included. In total, 10,556 records screened, 182 articles included final analysis, investigating 21 51 IMIDs. Forty-three phase 2 59 3 9 strategic 72 pilot case series considered. demonstrated both PLC-controlled head-to-head comparisons against active comparators, 93 102 randomised controlled (RCTs) meeting their primary endpoints. Since 2019, 8 have received approval by Federal Drug Agency European Medicine 11 IMIDs; these, 2, no approved disease-modifying antirheumatic drug (DMARD) therapy had previously been available. are effective treating various compounds recently approved. The impact (JAK) selectivity distinct JAK-STAT pathways needs further investigation, few also available sustained disease control upon tapering withdrawal optimal placement international algorithms.
Language: Английский
Citations
1
Journal of Clinical Investigation, Journal Year: 2024, Volume and Issue: 134(21)
Published: Oct. 31, 2024
Language: Английский
Citations
4
The Journal of Dermatology, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 15, 2025
Itch is a prominent symptom in many cutaneous disorders, including atopic dermatitis (AD), prurigo nodularis, and psoriasis. also common but overlooked concern patients with hidradenitis suppurativa (HS). Currently, the mechanisms underlying itch HS remain unclear. To gain better understanding, we reviewed literature on pruritus other itch-predominant AD, In HS, psoriasis, found that often co-localized pain occurred more frequently at night. Furthermore, was to negatively affect sleep increase risk for comorbid psychiatric disorders AD. However, HS-, psoriasis-, AD-related differ temporality. AD described as chronic, while psoriasis episodic. HS-associated likely multifactorial, several have been proposed peripheral sensitization, central neuroinflammation. Prior studies highlight enhanced IgE production dense infiltration of mast cells, along variety cytokines chemokines. alterations skin microbiome may contribute HS. date, few therapies studied treat Given efficacy biologics small molecules treating similar agents be explored future studies. Alternative target neurological contributions include anticonvulsants, cannabinoids, nonpharmacological treatments. conclusion, pathomechanisms fully elucidated. can draw lessons from pruritic begin addressing it identify important questions study.
Language: Английский
Citations
0
Dermatologic Clinics, Journal Year: 2025, Volume and Issue: 43(2), P. 231 - 245
Published: Jan. 21, 2025
Language: Английский
Citations
0
Dermatologic Clinics, Journal Year: 2025, Volume and Issue: 43(2), P. 359 - 371
Published: Jan. 21, 2025
Language: Английский
Citations
0
Annual Review of Medicine, Journal Year: 2025, Volume and Issue: 76(1), P. 69 - 80
Published: Jan. 27, 2025
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease characterized by the formation of nodules, abscesses, and fistulae at intertriginous sites. Pain, pruritus, malodor, suppuration have significant impact on quality life for HS patients. Prevalence figures vary greatly in literature from 0.05% to 4.1%, more common females. The current understanding etiology pathogenesis incomplete; numerous hypotheses concern interplay lifestyle factors, microbiota, genetics, dysregulated immune system. Due its phenotypic heterogeneity multifactorial pathogenesis, complex that can prove challenging manage. Two approved biologic therapies management led clinical response approximately 50% treated New targeting interleukin (IL)-1, IL-17, IL-36, Janus kinase/signal transducer activator transcription (JAK/STAT) pathways are ongoing trials, preliminary data offer hope greater efficacy future.
Language: Английский
Citations
0